Mariia Semenova
About Mariia Semenova
Mariia Semenova serves as the Head of Product Development at BADM Ltd., where she focuses on coaching, sales strategies, and partnerships to enhance pharmaceutical offerings in Ukraine. She leads the trademark registration process for new products and has a background in pharmacology.
Work at BADM
Mariia Semenova has been serving as the Head of Product Development at BADM Ltd. since 2017. In this role, she is responsible for identifying and launching new pharmaceutical products in the Ukrainian market. Her responsibilities include coaching and developing sales strategies for newly developed trademarks. Additionally, she actively seeks partnerships to enhance the company's pharmaceutical product offerings in Ukraine. Prior to her current position, she worked at BADM Ltd. as a project manager from 2011 to 2016.
Education and Expertise
Mariia Semenova completed her secondary education at High School №89, where she studied subjects including English, Physics, Biology, Chemistry, and Mathematics from 1994 to 2003. She then pursued higher education at Dnipropetrovs'ka Deržavna Medicna Akademija, earning a degree in Pharmacology from 2003 to 2008. Following her studies, she worked as a PhD Graduate Student at the same institution from 2008 to 2011, gaining expertise in her field.
Background
Mariia Semenova has a background in pharmacology and product development within the pharmaceutical industry. She has extensive experience in project management and product launch strategies, particularly in the Ukrainian market. Her career at BADM Ltd. has been marked by her involvement in trademark registration processes for new pharmaceutical products.
Achievements
Throughout her career, Mariia Semenova has contributed to the development and launch of various pharmaceutical products in Ukraine. Her role in coaching and sales strategies for newly developed trademarks has been significant in enhancing the market presence of these products. Additionally, her efforts in forming partnerships have aimed to strengthen the company's offerings in the pharmaceutical sector.